Eyenovia’s (EYEN) “Market Perform” Rating Reaffirmed at William Blair

William Blair reaffirmed their market perform rating on shares of Eyenovia (NASDAQ:EYEN) in a report published on Friday,Benzinga reports. William Blair also issued estimates for Eyenovia’s Q4 2024 earnings at ($0.08) EPS, FY2024 earnings at ($0.47) EPS, Q1 2025 earnings at ($0.12) EPS, Q2 2025 earnings at ($0.09) EPS, Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.08) EPS and FY2025 earnings at ($0.37) EPS.

Separately, HC Wainwright restated a “buy” rating and issued a $12.00 price objective on shares of Eyenovia in a research report on Wednesday.

Eyenovia Stock Down 70.0 %

Shares of Eyenovia stock traded down $0.24 during trading on Friday, hitting $0.10. 52,800,047 shares of the stock traded hands, compared to its average volume of 1,445,945. The firm has a market cap of $6.53 million, a P/E ratio of -0.14 and a beta of 1.75. The company has a current ratio of 0.74, a quick ratio of 0.27 and a debt-to-equity ratio of 0.58. Eyenovia has a 52-week low of $0.09 and a 52-week high of $2.57. The stock’s fifty day simple moving average is $0.49 and its 200 day simple moving average is $0.71.

Eyenovia (NASDAQ:EYEN) last posted its earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.02. Eyenovia had a negative return on equity of 1,108.24% and a negative net margin of 114,639.41%. During the same period last year, the firm earned ($0.18) EPS. On average, equities analysts predict that Eyenovia will post -0.56 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Michael M. Rowe purchased 50,000 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The shares were purchased at an average price of $0.57 per share, for a total transaction of $28,500.00. Following the purchase, the chief executive officer now directly owns 82,927 shares of the company’s stock, valued at $47,268.39. This represents a 151.85 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 7.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Eyenovia

Hedge funds have recently bought and sold shares of the stock. Armistice Capital LLC bought a new position in shares of Eyenovia in the second quarter worth $3,601,000. Vanguard Group Inc. lifted its stake in shares of Eyenovia by 25.2% in the first quarter. Vanguard Group Inc. now owns 1,790,501 shares of the company’s stock worth $1,765,000 after buying an additional 360,924 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in Eyenovia by 1,444.4% in the 1st quarter. BNP Paribas Financial Markets now owns 219,610 shares of the company’s stock valued at $217,000 after buying an additional 205,390 shares during the period. Geode Capital Management LLC grew its holdings in shares of Eyenovia by 36.6% in the 3rd quarter. Geode Capital Management LLC now owns 557,994 shares of the company’s stock worth $288,000 after purchasing an additional 149,471 shares during the last quarter. Finally, SkyView Investment Advisors LLC acquired a new position in Eyenovia during the 2nd quarter worth about $87,000. Hedge funds and other institutional investors own 25.84% of the company’s stock.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.